Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06673654 · ClinicalTrials.gov registry record · Phase 1
A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 476
- Enrollment target
NCT06673654: Completed Phase 1 study, sponsored by Sun Pharmaceutical Industries.
NCT06673654 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 476 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (693% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06673654, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 476 participants
- Enrollment target
Study Summary
To demonstrate the therapeutic equivalence and safety of Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) and OPZELURA (Ruxolitinib) Cream in the treatment of mild-to-moderate atopic dermatitis
Primary Outcome
The percentage of subjects in each treatment group with "Treatment Success" (defined as an IGA score of 0 (clear) or 1 (almost clear) with at least a two-point improvement from baseline, at the Week 8 (Day 56 ± 4 days) visit.
Interventions
- DRUG Placebo
- DRUG Ruxolitinib Topical Cream 1.5%
- DRUG OPZELURA (Ruxolitinib) Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 476 participants |
| Start Date | 2023-08-11 |
| Est. Completion | 2024-09-23 |
| Phase | Phase 1 |
What the finished NCT06673654 record still lists
NCT06673654 is an interventional study that assigns participants to a tested intervention. The registered 476 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (693% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06673654 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06673654 about?
NCT06673654 is a clinical study titled "A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.". To demonstrate the therapeutic equivalence and safety of Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) and OPZELURA (Ruxolitinib) Cream in the treatment of mild-to-moderate atopic dermatitis
What is the current status of trial NCT06673654?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 476 participants. The study started on 2023-08-11. Estimated completion is 2024-09-23.
What interventions are being tested in trial NCT06673654?
The interventions under investigation include: Placebo (DRUG), Ruxolitinib Topical Cream 1.5% (DRUG), OPZELURA (Ruxolitinib) Cream (DRUG).
Who is sponsoring clinical trial NCT06673654?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06673654's enrollment target sits among peer trials
476 51st of 2000 higher than 1,950 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06754046 · 476 participants · NA
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
- NCT06997497 · 477 participants · Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI